Biological Biooncology

Tecentriq

Payments companies reported to CMS as associated with Tecentriq. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.7Massociated payments (2023-2025)

6,697clinicians with associated payments

6companies reporting

By year

2023 $946K

2024 $402K

2025 $324K

Payments reported as associated with Tecentriq, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Hematology & Oncology $650K

Medical Oncology $357K

Thoracic Surgery (Cardiothoracic Vascular Surgery) $62K

Anatomic Pathology & Clinical Pathology $61K

Surgical Oncology $60K

Family $56K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Tecentriq

These are the largest totals companies reported as associated with Tecentriq. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Richard Finn	Santa Monica, CA	Hematology & Oncology	$116,699.12
Michael Morse	Durham, NC	Hematology & Oncology	$58,448.35
Mark Socinski	Orlando, FL	Hematology & Oncology	$52,306.38
Paulette Mhawech Fauceglia	Austin, TX	Anatomic Pathology & Clinical Pathology	$51,860.50
Adam Yopp	Dallas, TX	Surgical Oncology	$43,320.25
Stephen Liu	Los Angeles, CA	Medical Oncology	$41,561.96
Ahmed Kaseb	Detroit, MI	Medical Oncology	$40,818.08
Amit Singal	Dallas, TX	Hepatology	$35,077.08
Kathleen Kerrigan	Columbus, OH	Hematology & Oncology	$32,146.00
Hassane Zarour	Pittsburgh, PA		$29,291.89

Prescribed Tecentriq?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.